Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Tharimmune Inc (THAR)

Tharimmune Inc (THAR)
1.1500 x 1 1.3900 x 1
Pre-market by (Cboe BZX)
1.1697 +0.0197 (+1.71%) 04/22/25 [NASDAQ]
1.1500 x 1 1.3900 x 1
Pre-market 1.1697 unch (unch) 15:19 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.1200
Day High
1.1900
Open 1.1900
Previous Close 1.1697 1.1697
Volume 6,400 6,400
Avg Vol 100,235 100,235
Stochastic %K 35.27% 35.27%
Weighted Alpha -77.03 -77.03
5-Day Change -0.0045 (-0.38%) -0.0045 (-0.38%)
52-Week Range 0.9520 - 6.4485 0.9520 - 6.4485
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,467
  • Shares Outstanding, K 2,109
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,200 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -59.97
  • Growth Rate Est. (year over year) +1,765.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9520 +22.90%
on 04/07/25
Period Open: 1.4400
1.6885 -30.71%
on 03/24/25
-0.2700 (-18.75%)
since 03/21/25
3-Month
0.9520 +22.90%
on 04/07/25
Period Open: 2.0000
2.2000 -46.82%
on 01/23/25
-0.8300 (-41.50%)
since 01/22/25
52-Week
0.9520 +22.90%
on 04/07/25
Period Open: 5.5560
6.4485 -81.86%
on 05/09/24
-4.3860 (-78.94%)
since 04/22/24

Most Recent Stories

More News
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment...

THAR : 1.1700 (+1.74%)
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today...

THAR : 1.1700 (+1.74%)
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway

THAR : 1.1700 (+1.74%)
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today...

THAR : 1.1700 (+1.74%)
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today...

THAR : 1.1700 (+1.74%)
Tharimmune to Present at the Microcap Conference 2025

BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology...

THAR : 1.1700 (+1.74%)
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology...

THAR : 1.1700 (+1.74%)
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology...

THAR : 1.1700 (+1.74%)
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City,...

THAR : 1.1700 (+1.74%)
ACXP : 0.3767 (+2.09%)
UBI.AX : 0.062 (+1.64%)
GRF.VN : 0.470 (unch)
WISA : 1.2100 (-6.92%)
NNVC : 1.2930 (-3.51%)
ALCO : 29.34 (+1.77%)
MYPS : 1.2600 (unch)
ABL : 8.13 (-0.12%)
PERF : 1.6500 (+2.48%)
PETV : 0.5124 (-1.44%)
ABEO : 5.65 (+7.01%)
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City,...

ESGH.TO : 28.34 (+1.61%)
THAR : 1.1700 (+1.74%)
ACXP : 0.3767 (+2.09%)
GRF.VN : 0.470 (unch)
WISA : 1.2100 (-6.92%)
ALCO : 29.34 (+1.77%)
NNVC : 1.2930 (-3.51%)
ABL : 8.13 (-0.12%)
MYPS : 1.2600 (unch)
PERF : 1.6500 (+2.48%)
PETV : 0.5124 (-1.44%)
ABEO : 5.65 (+7.01%)

Business Summary

Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as Hillstream BioPharma Inc., is based in BRIDGEWATER, NJ.

See More

Key Turning Points

3rd Resistance Point 1.2700
2nd Resistance Point 1.2300
1st Resistance Point 1.2000
Last Price 1.1700
1st Support Level 1.1300
2nd Support Level 1.0900
3rd Support Level 1.0600

See More

52-Week High 6.4485
Fibonacci 61.8% 4.3488
Fibonacci 50% 3.7002
Fibonacci 38.2% 3.0517
Last Price 1.1700
52-Week Low 0.9520

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro